Articles Published in 2012

Insero Health completes phase I trial in drug resistant epilepsy

Thursday, December 13, 2012 08:00 AM

Insero Health, a clinical-stage company that develops small molecule therapies derived from natural products to treat neurological diseases, has completed a phase Ib trial of its lead compound INS001 in patients with drug-resistant epilepsy. 

More... »


Galderma to acquire Spirig Pharma

Wednesday, December 12, 2012 02:31 PM

Galderma Pharma, a Switzerland-based global specialty pharmaceutical company focused on dermatology, has entered into a definitive agreement to acquire Spirig Pharma, a Swiss company that develops, produces, and markets dermatological products.

More... »


Roche to invest $258M in diagnostics production in Germany

Wednesday, December 12, 2012 02:02 PM

Switzerland-based Roche has announced plans to invest over $258 million in its Penzberg biotechnology center, near Munich, Germany.

More... »

GSK, Vodafone to help increase childhood vaccination in Mozambique

Wednesday, December 12, 2012 11:44 AM

Global healthcare company GlaxoSmithKline (GSK) has formed a partnership with Vodafone, one of the world's largest mobile communications companies, to harness innovative mobile technology to help vaccinate more children against common infectious diseases in Africa.

More... »

Chiltern welcomes Cedric Burg and James Gunter

Wednesday, December 12, 2012 11:29 AM

Chiltern International, a global CRO, has appointed Dr. Cedric Burg and James Gunter to their team.

More... »

Gilead Sciences to acquire YM Biosciences

Wednesday, December 12, 2012 11:17 AM

Gilead Sciences, a biopharmaceutical company based in Foster City, Calif., has signed a definitive agreement to acquire YM BioSciences, a drug development company based in Canada, for $2.95 per share in cash. 

More... »

uniQure initiates phase I study in acute intermittent porphyria

Wednesday, December 12, 2012 10:48 AM

uniQure, a company that researches and develops human gene based therapies, has initiated its phase I clinical trial in acute intermittent porphyria (AIP).

More... »

GSK, Fred Hutchinson Cancer Research Center to develop muscular dystrophy therapeutics

Wednesday, December 12, 2012 10:19 AM

Fred Hutchinson Cancer Research Center and global healthcare company GlaxoSmithKline (GSK) have formed a partnership to develop therapeutics to treat an inherited form of muscular dystrophy.

More... »

Isis, AstraZeneca form strategic alliance on RNA therapeutics for cancer

Wednesday, December 12, 2012 09:51 AM

Isis Pharmaceuticals of Carlsbad, Calif., and global biopharmaceutical company AstraZeneca have formed a strategic alliance for the discovery and development of novel generation antisense therapeutics against five cancer targets, which includes a license to develop and commercialize ISIS-STAT3Rx, a drug Isis is currently evaluating in an early clinical trial in patients with advanced lymphomas.

More... »

Pernix Therapeutics to acquire Somaxon Pharmaceuticals

Wednesday, December 12, 2012 09:22 AM

Pernix Therapeutics, a specialty pharmaceutical company based in The Woodlands, Texas, has entered into a definitive merger agreement to acquire Somaxon Pharmaceuticals, a San Diego-based specialty pharmaceutical company, in a stock-for-stock transaction with a total equity value of $25 million.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 22

DaVita combines its two research CRO units to create an end-to-end CRO focused on kidney, end-stage renal disease

New crop of clinical trial matching services use patient’s molecular, genomic data for better fit

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs